

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



奧園健康生活集團有限公司

AOYUAN HEALTHY LIFE GROUP COMPANY LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3662)

INSIDE INFORMATION

This announcement is made by Aoyuan Healthy Life Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (a) the inside information announcement of the Company dated 30 March 2022 in relation to, among others, the delay in the publication of the annual results of the Group for the financial year ended 31 December 2021 (the “**2021 Annual Results**”) and the despatch of the Company’s annual report for the financial year ended 31 December 2021 (the “**2021 Annual Report**”); (b) the inside information announcement of the Company dated 3 May 2022 in relation to, among others, certain fund flows matters, the formation of the independent investigation committee of the Company and the appointment of independent professional advisers; (c) the inside information announcement of the Company dated 2 June 2022 in relation to, among others, the change of auditor of the Company and certain allegations against the Group; and (d) the inside information announcement of the Company dated 30 June 2022 in relation to, among others, the resumption guidance issued by the Stock Exchange (collectively, the “**Announcements**”). Unless otherwise stated, terms used in this announcement shall have the same respective meanings as those defined in the Announcements.

DELAY IN PUBLICATION OF INTERIM RESULTS AND DESPATCH OF INTERIM REPORT

Pursuant to Rules 13.49(6) and 13.48(1) of the Listing Rules, the Company is required to publish its preliminary results for the six months ended 30 June 2022 (the “**2022 Interim Results**”) not later than two months after the end of that period of six months, that is, on or before 31 August 2022 and despatch its interim report for the six months ended 30 June 2022 (the “**2022 Interim Report**”) to the Shareholders not later than three months after the end of that period of six months, that is, on or before 30 September 2022.

As disclosed in the Announcements, the Independent Investigation Committee has engaged the Investigation Firm to conduct investigations into the Fund Flows Matters and the Allegations. The Company has been actively cooperating with the Investigation Firm and as at the date of this announcement, the Investigation Firm is still conducting the investigations and preparing the reports on the findings. In view of the above, the publication of the 2021 Annual Results and the despatch of the 2021 Annual Report remain pending, as a result of which the 2022 Interim Results will not be ready for publication on or before 31 August 2022 and it is expected that there will also be a delay in the despatch of the 2022 Interim Report. The Company will continue to cooperate with and assist the Investigation Firm and the auditor of the Company in order to publish the 2021 Annual Results and the 2022 Interim Results and despatch the 2021 Annual Report and the 2022 Interim Report as soon as practicable.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 1 April 2022 and will continue to be suspended until further notice.

The Company will publish further announcement(s) in due course to inform the Shareholders and potential investors of the Company of any update on (a) the date of the meeting of the Board to approve the 2021 Annual Results and the 2022 Interim Results, (b) the audit process of the 2021 Annual Results and the 2022 Interim Results, (c) the date of despatch of the 2021 Annual Report and the 2022 Interim Report, (d) trading in the shares of the Company and (e) any material development in the process of the investigations on the Fund Flows Matters and the Allegations in accordance with the Listing Rules and applicable laws as and when appropriate.

By order of the Board
Aoyuan Healthy Life Group Company Limited
Guo Zining
Chairman

Hong Kong, 31 August 2022

As at the date of this announcement, the executive Directors are Mr. Zheng Wei and Mr. Cheng Siu Fai; the non-executive Directors are Mr. Guo Zining and Mr. Ruan Yongxi; and the independent non-executive Directors are Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao.